Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Authors

Elaine Huang (ORCID: https://orcid.org/0000-0003-2057-934X)
R. Alejandro Sica (ORCID: https://orcid.org/0000-0001-8877-4470)
P. Joy Ho (ORCID: https://orcid.org/0000-0002-2811-8671)
Wen‐Kai Weng (ORCID: https://orcid.org/0000-0001-8902-8189)
Qiuling Ally He (ORCID: https://orcid.org/0009-0002-7900-8736)
Shashwat Deepali Nagar (ORCID: https://orcid.org/0000-0001-7393-7054)
Leah M. Williams (ORCID: https://orcid.org/0000-0003-3121-1081)
Avanti Ganpule
Erika L. Cullingford
Boyu Hu (ORCID: https://orcid.org/0000-0001-9848-9497)
Anca A. Prica (ORCID: https://orcid.org/0000-0001-5621-9261)
Swaminathan P. Iyer (ORCID: https://orcid.org/0000-0002-1646-813X)
Auris Huen (ORCID: https://orcid.org/0000-0002-6403-7449)
Alissa Keegan (ORCID: https://orcid.org/0000-0001-5560-9989)
Jyoti D. Patel (ORCID: https://orcid.org/0000-0002-7550-2094)
Amer Beitinjaneh (ORCID: https://orcid.org/0000-0002-1661-5865)
Anna Ma (ORCID: https://orcid.org/0009-0005-4522-1768)
Michael S. Khodadoust (ORCID: https://orcid.org/0000-0001-9061-7351)
Sushant Karnik
Parin Sripakdeevong
Steven M. Horwitz (ORCID: https://orcid.org/0000-0002-6399-2006)
Mary‐Lee Dequéant (ORCID: https://orcid.org/0009-0005-8385-3547)
Francine M. Foss (ORCID: https://orcid.org/0000-0001-7843-3162)
Xijing He (ORCID: https://orcid.org/0000-0002-0465-5376)
Ziliang Li (ORCID: https://orcid.org/0000-0002-2080-1361)
Jasmine M. Zain (ORCID: https://orcid.org/0000-0003-4308-629X)
Youn H. Kim (ORCID: https://orcid.org/0000-0003-2686-5873)
Joy H Mendonez

Institutions

The University of Sydney (AU)
Albert Einstein College of Medicine (US)
Memorial Sloan Kettering Cancer Center (US)
Montefiore Medical Center (US)
The University of Texas MD Anderson Cancer Center (US)
University of Utah (US)
Royal Prince Alfred Hospital (AU)
Huntsman Cancer Institute (US)
Princess Margaret Cancer Centre (CA)
Yale University (US)
City of Hope (US)
University of Miami Hospital (US)
Sylvester Comprehensive Cancer Center (US)
Stanford University (US)

Publication Details

Journal: The Lancet Oncology
Published: 2024-11-28
DOI: https://doi.org/10.1016/s1470-2045(24)00508-4
Citations: 58
Primary Topic: CAR-T cell therapy research
Type: article
Field-Weighted Citation Impact: 16.10

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Elaine Huang, R. Alejandro Sica, P. Joy Ho, Wen‐Kai Weng, Qiuling Ally He, Shashwat Deepali Nagar, Leah M. Williams, Avanti Ganpule, Erika L. Cullingford, Boyu Hu, Anca A. Prica, Swaminathan P. Iyer, Auris Huen, Alissa Keegan, Jyoti D. Patel, Amer Beitinjaneh, Anna Ma, Michael S. Khodadoust, Sushant Karnik, Parin Sripakdeevong, Steven M. Horwitz, Mary‐Lee Dequéant, Francine M. Foss, Xijing He, Ziliang Li, Jasmine M. Zain, Youn H. Kim, Joy H Mendonez

November 28, 2024article en

58 citations

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Authors

Institutions

Publication Details

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.